PT - JOURNAL ARTICLE AU - Eyre, David W AU - Lumley, Sheila F AU - O’Donnell, Denise AU - Campbell, Mark AU - Sims, Elizabeth AU - Lawson, Elaine AU - Warren, Fiona AU - James, Tim AU - Cox, Stuart AU - Howarth, Alison AU - Doherty, George AU - Hatch, Stephanie B AU - Kavanagh, James AU - Chau, Kevin K AU - Fowler, Philip W AU - Swann, Jeremy AU - Volk, Denis AU - Yang-Turner, Fan AU - Stoesser, Nicole E AU - Matthews, Philippa C AU - Dudareva, Maria AU - Davies, Timothy AU - Shaw, Robert H AU - Peto, Leon AU - Downs, Louise O AU - Vogt, Alexander AU - Amini, Ali AU - Young, Bernadette C AU - Drennan, Philip AU - Mentzer, Alexander J AU - Skelly, Donal AU - Karpe, Fredrik AU - Neville, Matt J AU - Andersson, Monique AU - Brent, Andrew J AU - Jones, Nicola AU - Ferreira, Lucas Martins AU - Christott, Thomas AU - Marsden, Brian D AU - Hoosdally, Sarah AU - Cornall, Richard AU - Crook, Derrick W AU - Stuart, David AU - Screaton, Gavin AU - Oxford University Hospitals Staff Testing Group AU - Peto, Timothy EA AU - Holthof, Bruno AU - O’Donnell, Anne-Marie AU - Ebner, Daniel AU - Conlon, Christopher P AU - Jeffery, Katie AU - Walker, Timothy M TI - Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study AID - 10.1101/2020.06.24.20135038 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.24.20135038 4099 - http://medrxiv.org/content/early/2020/06/29/2020.06.24.20135038.1.short 4100 - http://medrxiv.org/content/early/2020/06/29/2020.06.24.20135038.1.full AB - Background Personal protective equipment (PPE) and social distancing are designed to mitigate risk of occupational SARS-CoV-2 infection in hospitals. Why healthcare workers nevertheless remain at increased risk is uncertain.Methods We conducted voluntary Covid-19 testing programmes for symptomatic and asymptomatic staff at a UK teaching hospital using nasopharyngeal PCR testing and immunoassays for IgG antibodies. A positive result by either modality determined a composite outcome. Risk-factors for Covid-19 were investigated using multivariable logistic regression.Results 1083/9809(11.0%) staff had evidence of Covid-19 at some time and provided data on potential risk-factors. Staff with a confirmed household contact were at greatest risk (adjusted odds ratio [aOR] 4.63 [95%CI 3.30-6.50]). Higher rates of Covid-19 were seen in staff working in Covid-19-facing areas (21.2% vs. 8.2% elsewhere) (aOR 2.49 [2.00-3.12]). Controlling for Covid-19-facing status, risks were heterogenous across the hospital, with higher rates in acute medicine (1.50 [1.05-2.15]) and sporadic outbreaks in areas with few or no Covid-19 patients. Covid-19 intensive care unit (ICU) staff were relatively protected (0.46 [0.29-0.72]). Positive results were more likely in Black (1.61 [1.20-2.16]) and Asian (1.58 [1.34-1.86]) staff, independent of role or working location, and in porters and cleaners (1.93 [1.25-2.97]). Contact tracing around asymptomatic staff did not lead to enhanced case identification. 24% of staff/patients remained PCR-positive at ≥6 weeks post-diagnosis.Conclusions Increased Covid-19 risk was seen in acute medicine, among Black and Asian staff, and porters and cleaners. A bundle of PPE-related interventions protected staff in ICU.Competing Interest StatementDWE has received lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.Funding StatementThis study was funded by the UK Government's Department of Health and Social Care. This work was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) [grant HPRU-2012-10041] and the NIHR Biomedical Research Centre, Oxford. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health or Public Health England. DWE is a Robertson Foundation Fellow and an NIHR Oxford BRC Senior Fellow. SFL is a Wellcome Trust Clinical Research Fellow. DIS is supported by the Medical Research Council (MR/N00065X/1). PCM holds a Wellcome Intermediate Fellowship (110110/Z/15/Z) and an NIHR Oxford BRC Senior Fellow. MD is an NIHR Doctoral Research Fellow. KKC is a Medical Research Foundation National PhD Training Programme student (MRF-145-004-TPG-AVISO)[Others to add]. AA is a Wellcome Trust Clinical Research Training Fellow (216417/Z/19/Z). BCY is an NIHR Clinical Lecturer. LMF, TC and BDM are supported by the SGC, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and Wellcome. BDM is supported by the Kennedy Trust for Rheumatology Research. GS is a Wellcome Trust Senior Investigator and acknowledges funding from the Schmidt Foundation. TMW is a Wellcome Trust Clinical Career Development Fellow (214560/Z/18/Z). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data collection and testing were part of enhanced hospital infection prevention and control measures instituted by the UK Department of Health and Social Care.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request subject via the Infections in Oxfordshire Research Database subject to applicants meeting the ethical and governance requirements of the Database.